DOCSLIB.ORG

An Integrated Genomic Approach Identifies ARID1A As a Candidate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Integrated Genomic Approach Identifies ARID1A As a Candidate Oncogene (2012) 31, 2090–2100 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc ORIGINAL ARTICLE An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer A Mamo1,9, L Cavallone2,9, S Tuzmen3, C Chabot1, C Ferrario1, S Hassan1, H Edgren4,5, O Kallioniemi4,5, O Aleynikova6, E Przybytkowski1, K Malcolm1, S Mousses3, PN Tonin2,7,8 and M Basik1 1Department of Oncology, Lady Davis Institute, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Que´bec, Canada; 2Department of Human Genetics, McGill University, Montreal, Que´bec, Canada; 3Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, AZ, USA; 4University of Helsinki, Institute for Molecular Medicine (FIMM), Helsinki, Finland; 5VTT Technical Research Centre of Finland and University of Turku, Medical Biotechnology, Turku, Finland; 6Department of Pathology, Jewish General Hospital, Montreal, Que´bec, Canada; 7Department of Medicine, McGill University, Montreal, Que´bec, Canada and 8The Research Institute of the McGill University Health Centre, Montreal, Que´bec, Canada Tumor-suppressor genes (TSGs) have been classically defined Introduction as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. Cancers occur as a result of dysregulation in the TSGs containing nonsense mutations may not be expressed function of oncogenes and tumor-suppressor genes because of nonsense-mediated RNA decay (NMD). We (TSGs). TSGs have been classically defined as genes combined inhibition of the NMD process, which clears whose loss of function in tumor cells contributes to the transcripts that contain nonsense mutations, with the applica- formation and/or maintenance of the tumor phenotype tion of high-density single-nucleotide polymorphism arrays (Presneau et al., 2003). Various mechanisms of inactiva- analysis to discriminate allelic content in order to identify tion of TSGs have been reported and can include candidate TSGs in five breast cancer cell lines. We identified deletion of one allele through chromosomal non- ARID1A as a target of NMD in the T47D breast cancer cell dysjunction and/or intra-chromosomal rearrangement, line, likely as a consequence of a mutation in exon-9, which and mutational inactivation of the remaining allele introduces a premature stop codon at position Q944. (Presneau et al., 2003). TSGs have been identified in ARID1A encodes a human homolog of yeast SWI1, which cancer both as a result of a search for germline is an integral member of the hSWI/SNF complex, an ATP- mutations in hereditary cancers and the molecular dependent, chromatin-remodeling, multiple-subunit enzyme. characterization of somatic deletions and mutations in Although we did not find any somatic mutations in 11 breast tumor tissue RNA and DNA (Vogelstein and Kinzler, tumors, which show DNA copy-number loss at the 1p36 locus 2004). However, TSGs containing nonsense mutations adjacent to ARID1A, we show that low ARID1A RNA or may not be detectable using RNA-based next-genera- nuclear protein expression is associated with more aggressive tion re-sequencing because RNA containing such breast cancer phenotypes, such as high tumor grade, in two aberrant transcripts is eliminated by the nonsense- independent cohorts of over 200 human breast cancer cases mediated RNA decay process (NMD) (Noensie and each. We also found that low ARID1A nuclear expression Dietz, 2001). Indeed, an interesting strategy to discover becomes more prevalent during the later stages of breast potential TSG candidates was elaborated by Noensie tumor progression. Finally, we found that ARID1A re- and Dietz (2001) and adapted by Huusko et al. (2004). expression in the T47D cell line results in significant inhibition Noensie and Dietz (2001) proposed that it would be of colony formation in soft agar. These results suggest that possible to discover nonsense mutation containing ARID1A may be a candidate TSG in breast cancer. mRNA by inhibiting the NMD process. In this way, Oncogene (2012) 31, 2090–2100; doi:10.1038/onc.2011.386; transcripts containing nonsense mutations are stabilized published online 5 September 2011 and selectively increase in quantity relative to non- mutated transcripts. Huusko et al. (2004) then combined Keywords: ARID1A; nonsense-mediated mRNA decay; NMD inhibition with array comparative genomic tumor-suppressor gene; breast cancer hybridization (aCGH) in order to enrich for the selection of candidates mapping to deleted regions in prostate cancer cell lines, thereby identifying EPHB2 as Correspondence: Dr M Basik, Department of Oncology, Lady Davis a novel candidate TSG in prostate cancer. Institute, Sir Mortimer B Davis Jewish General Hospital, McGill We have adapted the approach of Huusko et al. by University, 3755 Cote Ste-Catherine, Montre´al, Que´bec, Canada integrating the allelic content inferred from high-density H3T 1E2. genotyping single-nucleotide polymorphism (SNP) E-mail: [email protected] arrays to identify candidates TSGs in five breast cancer 9These authors contributed equally to this work as first co-authors. Received 16 February 2011; revised 6 July 2011; accepted 26 July 2011; cell lines. Here we report the discovery of ARID1A as a published online 5 September 2011 candidate TSG in the T47D breast cancer cell line by Inactivation of ARID1A in breast cancer A Mamo et al 2091 using this approach. ARID1A encodes a human were identified. The percentage of total transcripts homolog of yeast SWI1, which contains a DNA-binding mapping to LOH regions with an NMD ratio >2 motif (AT-rich interactive domain, ARID) and is an ranged from 1.4 to 4% of all transcripts (Supplementary integral member of the hSWI/SNF complex, an ATP- Figure 2). Reasoning that under-expression is a pheno- dependent, chromatin-remodeling, multiple-subunit en- type of classical TSGs, we then selected candidates zyme (Takeuchi et al., 1997, 1998; Dallas et al., 1998, showing levels of gene expression below the overall 2000; Wang et al., 2004; Wilsker et al., 2004; Patsialou median value of expression for each cell line. Using this et al., 2005). An increasing body of evidence has strategy, the number of candidates decreased to 0.6– demonstrated that SWI/SNF complexes have important 1.9% of total transcripts depending on the cell line roles in gene regulation (Winston and Carlson, 1992; (Supplementary Figure 2). To prioritize candidates for Carlson and Laurent, 1994; Hirschhorn et al., 1995; further analysis, we selected those genes, which showed Kennison, 1995; Sudarsanam et al., 1999, 2000), cell an NMD ratio >2 uniquely in one of the five breast proliferation (Nagl et al., 2005, 2006, 2007) and cancer cell lines. The rationale was based on the development (Carlson and Laurent, 1994; Kennison, assumption that if one gene harbors a nonsense 1995). Several genes encoding hSWI/SNF components mutation in a given cell line, it would be very unlikely have been associated with tumorigenesis (Medina and that the same gene would have a nonsense mutation in Sanchez-Cespedes, 2008; Roberts and Biegel, 2009; another cell line of a small sample set because of the very Rodriguez-Nieto and Sanchez-Cespedes, 2009). More- low frequency of nonsense mutations in tumor cells over, Huang et al. (2007) reported that an antisense (Sjoblom et al., 2006). Applying this selection strategy to cDNA resulting from a genomic rearrangement invol- all five breast cancer cell lines led to the selection of 53 ving the ARID1A gene in a primary breast carcinoma candidate TSGs, or 0.03% of the total number of could transform NIH3T3 cells. During the course of our transcripts on this microarray platform (Supplementary investigation, mutations in the ARID1A were reported Figure 1 and Table 1). to occur in up to 50% of ovarian clear cell carcinomas Sequencing of the 53 candidate genes was begun in the (Jones et al., 2010; Wiegand et al., 2010). Thus ARID1A respective cell lines used for their selection. We began appears to show all of the hallmarks of a classical validating our list starting with genes that have been TSG (Presneau et al., 2003). reported to possess potential tumor-suppressive function We also report on ARID1A expression in human or to be involved in breast cancer. A total of 15 genes breast cancers. We found that low ARID1A RNA and/ were sequenced before we found a nonsense mutation in or nuclear protein expression is associated with more CDH1 in the MDA-MB-453 cell line. CDH1 encodes aggressive breast cancer phenotypes. Finally, we found cadherin-1 and is known to be mutated in the MDA-MB- that ARID1A re-expression in the T47D breast cancer 453 cell line (Forbes et al., 2010), a mutation, which was cell line results in significant inhibition of colony verified in our laboratory by DNA sequencing. CDH1 or formation in soft agar. These results suggest that the cadherin is a well-known TSG, responsible for a ARID1A may be a TSG in breast cancer, and that it hereditary cancer syndrome (Campeau et al., 2008). warrants further investigation as a potential diagnostic As Huang et al. (2007) reported that the ARID1A and therapeutic marker in breast cancer. gene was genomically rearranged in a primary breast carcinoma, we also focused on the ARID1A gene in our list. We identified a nonsense mutation, c.944C>T, in exon-9 in the ARID1A gene, which introduces a Results premature stop codon at amino-acid position 944 (Figure 1a). We confirmed that the RNA levels of NMD inhibition combined with genomic analysis identifies ARID1A were very low and increased when the T47D ARID1A as a potential candidate TSG in breast cancer cell line was treated with emetine, the NMD inhibitor A modification of a strategy described by Huusko et al. (Figure 1b). ARID1A is located at chromosomal band (2004) was used to identify transcripts with nonsense 1p36.11, mapping within the LOH region shown by the mutations.
Load more

Recommended publications
  • The DEAD-Box RNA Helicase-Like Utp25 Is an SSU Processome Component
    Downloaded from rnajournal.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press The DEAD-box RNA helicase-like Utp25 is an SSU processome component J. MICHAEL CHARETTE1,2 and SUSAN J. BASERGA1,2,3 1Department of Molecular Biophysics & Biochemistry, Yale University School of Medicine, New Haven, Connecticut 06520, USA 2Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA 3Department of Genetics, Yale University School of Medicine, New Haven, Connecticut 06520, USA ABSTRACT The SSU processome is a large ribonucleoprotein complex consisting of the U3 snoRNA and at least 43 proteins. A database search, initiated in an effort to discover additional SSU processome components, identified the uncharacterized, conserved and essential yeast nucleolar protein YIL091C/UTP25 as one such candidate. The C-terminal DUF1253 motif, a domain of unknown function, displays limited sequence similarity to DEAD-box RNA helicases. In the absence of the conserved DEAD-box sequence, motif Ia is the only clearly identifiable helicase element. Since the yeast homolog is nucleolar and interacts with components of the SSU processome, we examined its role in pre-rRNA processing. Genetic depletion of Utp25 resulted in slowed growth. Northern analysis of pre-rRNA revealed an 18S rRNA maturation defect at sites A0,A1, and A2. Coimmunoprecipitation confirmed association with U3 snoRNA and with Mpp10, and with components of the t-Utp/UtpA, UtpB, and U3 snoRNP subcomplexes. Mutation of the conserved motif Ia residues resulted in no discernable temperature- sensitive or cold-sensitive growth defects, implying that this motif is dispensable for Utp25 function.
    [Show full text]
  • Analysis of Gene Expression Data for Gene Ontology
    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
    [Show full text]
  • Kras Mutant Genetically Engineered Mouse Models of Human Cancers
    Kras mutant genetically engineered mouse models of PNAS PLUS human cancers are genomically heterogeneous Wei-Jen Chunga,1,2, Anneleen Daemena,1, Jason H. Chengb, Jason E. Longb, Jonathan E. Cooperb, Bu-er Wangb, Christopher Tranb, Mallika Singhb,3, Florian Gnada,4, Zora Modrusanc, Oded Foremand, and Melissa R. Junttilab,5 aBioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA 94080; bTranslational Oncology, Genentech, Inc., South San Francisco, CA 94080; cMolecular Biology, Genentech, Inc., South San Francisco, CA 94080; and dPathology, Genentech, Inc., South San Francisco, CA 94080 Edited by Anton Berns, The Netherlands Cancer Institute, Amsterdam, The Netherlands, and approved November 6, 2017 (received for review May 23, 2017) KRAS mutant tumors are largely recalcitrant to targeted therapies. treatment susceptibility and tumor evolution under selective pres- Genetically engineered mouse models (GEMMs) of Kras mutant sure of drug therapy. cancer recapitulate critical aspects of this disease and are widely used for preclinical validation of targets and therapies. Through Results comprehensive profiling of exomes and matched transcriptomes Spontaneous Acquisition of Genomic Aberrations in KrasG12D-Initiated of >200 KrasG12D-initiated GEMM tumors from one lung and two GEMM Tumors. To better define the genomic landscape of estab- pancreatic cancer models, we discover that significant intratumoral lished Kras mutant tumor models, we focused on three models of and intertumoral genomic heterogeneity evolves during tumorigen- Kras mutant cancer: a nonsmall cell lung cancer (NSCLC) model esis. Known oncogenes and tumor suppressor genes, beyond those with adenovirus-induced expression of KrasG12D and homozygous engineered, are mutated, amplified, and deleted. Unlike human tu- p53 targeting (KP:KrasLSL.G12D/wt;p53frt/frt) (11, 13), and two models mors, the GEMM genomic landscapes are dominated by copy num- ber alterations, while protein-altering mutations are rare.
    [Show full text]
  • Utpa and Utpb Chaperone Nascent Pre-Ribosomal RNA and U3 Snorna to Initiate Eukaryotic Ribosome Assembly
    ARTICLE Received 6 Apr 2016 | Accepted 27 May 2016 | Published 29 Jun 2016 DOI: 10.1038/ncomms12090 OPEN UtpA and UtpB chaperone nascent pre-ribosomal RNA and U3 snoRNA to initiate eukaryotic ribosome assembly Mirjam Hunziker1,*, Jonas Barandun1,*, Elisabeth Petfalski2, Dongyan Tan3, Cle´mentine Delan-Forino2, Kelly R. Molloy4, Kelly H. Kim5, Hywel Dunn-Davies2, Yi Shi4, Malik Chaker-Margot1,6, Brian T. Chait4, Thomas Walz5, David Tollervey2 & Sebastian Klinge1 Early eukaryotic ribosome biogenesis involves large multi-protein complexes, which co-transcriptionally associate with pre-ribosomal RNA to form the small subunit processome. The precise mechanisms by which two of the largest multi-protein complexes—UtpA and UtpB—interact with nascent pre-ribosomal RNA are poorly understood. Here, we combined biochemical and structural biology approaches with ensembles of RNA–protein cross-linking data to elucidate the essential functions of both complexes. We show that UtpA contains a large composite RNA-binding site and captures the 50 end of pre-ribosomal RNA. UtpB forms an extended structure that binds early pre-ribosomal intermediates in close proximity to architectural sites such as an RNA duplex formed by the 50 ETS and U3 snoRNA as well as the 30 boundary of the 18S rRNA. Both complexes therefore act as vital RNA chaperones to initiate eukaryotic ribosome assembly. 1 Laboratory of Protein and Nucleic Acid Chemistry, The Rockefeller University, New York, New York 10065, USA. 2 Wellcome Trust Centre for Cell Biology, University of Edinburgh, Michael Swann Building, Max Born Crescent, Edinburgh EH9 3BF, UK. 3 Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
    [Show full text]
  • Broad Susceptibility of Nucleolar Proteins and Autoantigens to Complement C1 Protease Degradation
    Broad Susceptibility of Nucleolar Proteins and Autoantigens to Complement C1 Protease Degradation This information is current as Yitian Cai, Seng Yin Kelly Wee, Junjie Chen, Boon Heng of September 25, 2021. Dennis Teo, Yee Leng Carol Ng, Khai Pang Leong and Jinhua Lu J Immunol published online 25 October 2017 http://www.jimmunol.org/content/early/2017/10/25/jimmun ol.1700728 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/10/25/jimmunol.170072 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 25, 2017, doi:10.4049/jimmunol.1700728 The Journal of Immunology Broad Susceptibility of Nucleolar Proteins and Autoantigens to Complement C1 Protease Degradation Yitian Cai,*,1 Seng Yin Kelly Wee,*,1 Junjie Chen,* Boon Heng Dennis Teo,* Yee Leng Carol Ng,† Khai Pang Leong,† and Jinhua Lu* Anti-nuclear autoantibodies, which frequently target the nucleoli, are pathogenic hallmarks of systemic lupus erythematosus (SLE).
    [Show full text]
  • Rrp9 As a Potential Novel Antifungal Target in Candida Albicans: Evidences from in Silico Studies Awad Ali, Archana Wakharde and Sankunny Mohan Karuppayil*
    Research Article iMedPub Journals Medical Mycology: Open Access 2017 http://www.imedpub.com/ Vol.3 No.2:26 ISSN 2471-8521 DOI: 10.4172/2167-7972.100026 Rrp9 as a Potential Novel Antifungal Target in Candida albicans: Evidences from In Silico Studies Awad Ali, Archana Wakharde and Sankunny Mohan Karuppayil* School of Life Sciences (DST-FIST&UGC-SAP Sponsored), S.R.T.M. University (NAAC Accredited with "A" grade), Nanded, 431606, Maharashtra state, India *Corresponding author: Sankunny Mohan Karuppayil, Professor and Director, School of Life Sciences (DST-FIST&UGC-SAP Sponsored), S.R.T.M. University (NAAC Accredited with "A" grade), Nanded, 431606, Maharashtra state, India, Tel: +919764386253; E-mail: [email protected] Received date: November 06, 2017; Accepted date: November 22, 2017; Published date: November 30, 2017 Citation: Ali A, Wakharde A, Karuppayil SM (2017) Rrp9 as a Potential Novel Antifungal Target in Candida albicans: Evidences from In Silico Studies. Med Mycol Open Access Vol.3 No. 2: 26. Copyright: ©2017 Ali A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Human G-protein coupled receptors (GPCRs) are complex compared to C. albicans GPCR. C. albicans has GPCR proteins Abstract such as Gpr1, Ste2, and Ste3. Gpr1 is a glucose sensor that plays important roles in morphogenesis [4]. Ste2 and Ste3 are Dicyclomine is a selective muscarinic M1 receptor pheromone receptors which play roles in mating and antagonist in humans.
    [Show full text]
  • The Complete Structure of the Small-Subunit Processome
    ARTICLES The complete structure of the small-subunit processome Jonas Barandun1,4 , Malik Chaker-Margot1,2,4 , Mirjam Hunziker1,4 , Kelly R Molloy3, Brian T Chait3 & Sebastian Klinge1 The small-subunit processome represents the earliest stable precursor of the eukaryotic small ribosomal subunit. Here we present the cryo-EM structure of the Saccharomyces cerevisiae small-subunit processome at an overall resolution of 3.8 Å, which provides an essentially complete near-atomic model of this assembly. In this nucleolar superstructure, 51 ribosome-assembly factors and two RNAs encapsulate the 18S rRNA precursor and 15 ribosomal proteins in a state that precedes pre-rRNA cleavage at site A1. Extended flexible proteins are employed to connect distant sites in this particle. Molecular mimicry and steric hindrance, as well as protein- and RNA-mediated RNA remodeling, are used in a concerted fashion to prevent the premature formation of the central pseudoknot and its surrounding elements within the small ribosomal subunit. Eukaryotic ribosome assembly is a highly dynamic process involving during which the four rRNA domains of the 18S rRNA (5′, central, in excess of 200 non-ribosomal proteins and RNAs. This process 3′ major and 3′ minor) are bound by a set of specific ribosome-assem- starts in the nucleolus where rRNAs for the small ribosomal subunit bly factors7,8. Biochemical studies indicated that these factors and the (18S rRNA) and the large ribosomal subunit (25S and 5.8S rRNA) 5′-ETS particle probably contribute to the independent maturation are initially transcribed as part of a large 35S pre-rRNA precursor of the domains of the SSU7,8.
    [Show full text]
  • Interdependent Action of KH Domain Proteins Krr1 and Dim2 Drive the 40S Platform Assembly
    ARTICLE DOI: 10.1038/s41467-017-02199-4 OPEN Interdependent action of KH domain proteins Krr1 and Dim2 drive the 40S platform assembly Miriam Sturm1, Jingdong Cheng 2, Jochen Baßler 1, Roland Beckmann2 & Ed Hurt 1 Ribosome biogenesis begins in the nucleolus with the formation of 90S pre-ribosomes, from which pre-40S and pre-60S particles arise that subsequently follow separate maturation pathways. Here, we show how structurally related assembly factors, the KH domain proteins 1234567890 Krr1 and Dim2, participate in ribosome assembly. Initially, Dim2 (Pno1) orchestrates an early step in small subunit biogenesis through its binding to a distinct region of the 90S pre- ribosome. This involves Utp1 of the UTP-B module, and Utp14, an activator of the DEAH-box helicase Dhr1 that catalyzes the removal of U3 snoRNP from the 90S. Following this dis- mantling reaction, the pre-40S subunit emerges, but Dim2 relocates to the pre-40S platform domain, previously occupied in the 90S by the other KH factor Krr1 through its interaction with Rps14 and the UTP-C module. Our findings show how the structurally related Krr1 and Dim2 can control stepwise ribosome assembly during the 90S-to-pre-40S subunit transition. 1 Biochemistry Centre, University of Heidelberg, Heidelberg 69221, Germany. 2 Department of Biochemistry, Gene Center, Center for integrated Protein Science - Munich (CiPS-M), Ludwig-Maximillian University, Munich 81377, Germany. Correspondence and requests for materials should be addressed to E.H. (email: [email protected]) NATURE COMMUNICATIONS | 8: 2213 | DOI: 10.1038/s41467-017-02199-4 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02199-4 he biogenesis of eukaryotic ribosomes is a complex and compacted, processes during which they migrate from the extremely energy-consuming process, during which nucleolus to the nucleoplasm, before export into the cytoplasm, T 2–4 actively growing cells devote most of their RNA poly- where final maturation occurs .
    [Show full text]
  • Yeast Rrp9p Is an Evolutionarily Conserved U3 Snornp Protein Essential for Early Pre-Rrna Processing Cleavages and Requires Box C for Its Association
    Downloaded from rnajournal.cshlp.org on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press RNA (2000), 6:1660–1671+ Cambridge University Press+ Printed in the USA+ Copyright © 2000 RNA Society+ Yeast Rrp9p is an evolutionarily conserved U3 snoRNP protein essential for early pre-rRNA processing cleavages and requires box C for its association JAAP VENEMA,1,3 HARMJAN R. VOS,1 ALEX W. FABER,1 WALTHER J. VAN VENROOIJ,2 and HENDRIK A. RAUÉ1 1 Department of Biochemistry and Molecular Biology, Instituut Moleculaire Biologische Wetenschappen, BioCentrum Amsterdam, Vrije Universiteit, Amsterdam, The Netherlands 2 Department of Biochemistry, University of Nijmegen, The Netherlands ABSTRACT Pre-rRNA processing in eukaryotic cells requires participation of several snoRNPs. These include the highly con- served and abundant U3 snoRNP, which is essential for synthesis of 18S rRNA. Here we report the characterization of Rrp9p, a novel yeast U3 protein, identified via its homology to the human U3-55k protein. Epitope-tagged Rrp9p specifically precipitates U3 snoRNA, but Rrp9p is not required for the stable accumulation of this snoRNA. Genetic depletion of Rrp9p inhibits the early cleavages of the primary pre-rRNA transcript at A0,A1, and A2 and, consequently, production of 18S, but not 25S and 5.8S, rRNA. The hU3-55k protein can partially complement a yeast rrp9 null mutant, indicating that the function of this protein has been conserved. Immunoprecipitation of extracts from cells that coexpress epitope-tagged Rrp9p and various mutant forms of U3 snoRNA limits the region required for association of Rrp9p to the U3-specific box B/C motif.
    [Show full text]
  • RNA Polymerase I Transcription and Pre-Rrna Processing Are Linked by Specific SSU Processome Components
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press RNA polymerase I transcription and pre-rRNA processing are linked by specific SSU processome components Jennifer E.G. Gallagher,2 David A. Dunbar,3 Sander Granneman,1 Brianna M. Mitchell,3 Yvonne Osheim,4 Ann L. Beyer,4 and Susan J. Baserga1,2,3,5 1Department of Molecular Biophysics and Biochemistry, 2Department of Genetics, and 3Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520-8024, USA; 4Department of Microbiology, University of Virginia, Charlottesville, Virginia 22904, USA Sequential events in macromolecular biosynthesis are often elegantly coordinated. The small ribosomal subunit (SSU) processome is a large ribonucleoprotein (RNP) required for processing of precursors to the small subunit RNA, the 18S, of the ribosome. We have found that a subcomplex of SSU processome proteins, the t-Utps, is also required for optimal rRNA transcription in vivo in the yeast Saccharomyces cerevisiae.The t-Utps are ribosomal chromatin (r-chromatin)-associated, and they exist in a complex in the absence of the U3 snoRNA. Transcription is required neither for the formation of the subcomplex nor for its r-chromatin association. The t-Utps are associated with the pre-18S rRNAs independent of the presence of the U3 snoRNA. This association may thus represent an early step in the formation of the SSU processome. Our results indicate that rRNA transcription and pre-rRNA processing are coordinated via specific components of the SSU processome. [Keywords: Ribosome; RNA; transcription; RNA processing; SSU processome] Received May 27, 2004; revised version accepted August 19, 2004.
    [Show full text]
  • A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family Linda Molla Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Linda Molla June 2018 © Copyright by Linda Molla 2018 A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY Linda Molla, Ph.D. The Rockefeller University 2018 APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins. Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous research has implicated APOBEC2 in diverse organisms and cellular processes such as muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I have combined Next Generation Sequencing (NGS) techniques with state-of-the-art molecular biology to determine the physiological targets of APOBEC2. Using a cell culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1, APOBEC2 is not an RNA editor. Using the same system combined with enhanced Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C deaminase.
    [Show full text]
  • A SARS-Cov-2 Protein Interaction Map Reveals Targets for Drug Repurposing
    Article A SARS-CoV-2 protein interaction map reveals targets for drug repurposing https://doi.org/10.1038/s41586-020-2286-9 A list of authors and affiliations appears at the end of the paper Received: 23 March 2020 Accepted: 22 April 2020 A newly described coronavirus named severe acute respiratory syndrome Published online: 30 April 2020 coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than Check for updates 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efcacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and eforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identifed the human proteins that physically associated with each of the SARS-CoV-2 proteins using afnity-purifcation mass spectrometry, identifying 332 high-confdence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.
    [Show full text]